Dr. Rebecca Laborde, postdoctoral research fellow at Mayo Clinic in Rochester, Minnesota, shares the results of a study appearing in the March 2012 issue of Mayo Clinic Proceedings, that supports the application of mRNA-seq technology as a way to more accurately stratify patients based on individual tumor biology to improve the understanding of tumor prognosis and treatment responses that would improve individualized patient care strategies.